How to Get Zepbound Covered by Insurance: Prior Authorization and Appeal Steps

To get Zepbound covered, first confirm your health plan’s formulary tier and prior-authorization criteria, then have your prescriber submit the required medical records-body-mass-index, weight history, and comorbidity documentation-along with the coverage form. If your request is denied, file a timely appeal with a tailored letter of medical necessity and, if needed, request an external review. While the process can take several weeks, most successful approvals share complete clinical data, evidence of previous weight-loss efforts, and clear alignment with the plan’s policy.

• Most commercial plans place Zepbound on a preferred specialty tier that still requires prior authorization and, in 43% of cases, step therapy with another GLP-1 first (formularylookup.com).
• Common requirements include a starting BMI of at least 30, or 27 with one weight-related condition such as hypertension, plus documentation of a 6-month lifestyle program.
• The Lilly Zepbound Savings Card caps monthly copays at as little as $25 for up to 12 fills per calendar year if your plan covers the drug; LillyDirect cash pricing is $550 per pen when coverage is denied (lilly.com).

What Zepbound Is and Why Insurers Require Extra Paperwork

Zepbound is the brand-name, FDA-approved version of tirzepatide for chronic weight management in adults with a body-mass-index (BMI) of 30 kg/m² or higher, or 27 kg/m² or higher with at least one weight-related comorbidity (DailyMed). Tirzepatide acts on both GLP-1 and GIP receptors to reduce appetite and improve glucose control.

Because Zepbound is a high-cost, specialty medication, insurers use utilization-management tools-prior authorization (PA), step therapy, and quantity limits-to control spending and ensure the drug is used in patients most likely to benefit. Understanding these rules is the first step toward coverage.

See current retail pricing on Zepbound, or compare cash prices at local pharmacies instantly with a free Rx.com discount card.

How Insurers Decide Whether to Cover Zepbound

Insurers weigh clinical trial data, FDA labeling, budget impact, and pharmacy-benefit-manager (PBM) rebate agreements when they set coverage policy. Here are the main levers:

Formulary tier: Zepbound typically lands on a specialty tier (Tier 4 or Tier 5) with coinsurance up to 50% unless you hit an out-of-pocket maximum.

Prior authorization: Nearly all commercial, Medicare Part D, and exchange plans require PA for new prescriptions. Medicaid programs often publish a separate criteria checklist.

Step therapy: Some plans make patients try and “fail” another GLP-1 such as Wegovy first. According to one national PBM, 43% of employer plans added a one-drug step in 2026 (CVS Caremark).

Quantity limits: Dosing pens are dispensed in 28-day supplies. Requests for early refills or higher strengths must justify medical need.

The Prior Authorization Checklist

Submitting every document your plan asks for the first time prevents back-and-forth delays.

Mandatory elements:

• Completed PA form: Use the insurer’s own PDF if possible; electronic portals often pre-fill member data.
• Recent chart notes: Include height, weight, and calculated BMI within the last 30 days.
• Comorbidity proof: Labs or diagnosis codes for hypertension, dyslipidemia, obstructive sleep apnea, or prediabetes.
• 6-month weight history: Many plans require documentation that weight did not improve sufficiently with diet and exercise.
• Medication history: List any prior anti-obesity drugs, duration, and response. This satisfies step-therapy logic or shows intolerance.
• Letter of medical necessity (LMN): A concise, one-page narrative linking the patient’s condition to policy language boosts approval odds (Marshall et al., 2026).

Handling Step Therapy and Quantity Limits

About four in ten plans require “step therapy,” meaning you must demonstrate failure or intolerance to another medication before Zepbound is covered.

Documenting a step: Provide pharmacy fill records or an attestation that the alternative drug was tried for the required length (usually 12 weeks) without adequate weight reduction.

Medical exceptions: If the step drug is contraindicated-say the patient cannot tolerate Trulicity because of severe GI side effects-cite the adverse reaction and product labeling to request a bypass.

Quantity limit overrides: Plans may automatically limit the starting dose to a 2.5 mg pen. If your prescriber wants to start at 5 mg, note this in the PA rationale and reference the FDA titration schedule.

Appealing a Denial: Templates and Timelines

If the prior authorization comes back denied, do not give up. Insurers must allow at least one internal appeal and, under the Affordable Care Act, an external review by an independent organization.

1. Read the denial letter carefully: Identify which criteria were “not met.”

2. Collect missing evidence: Often the denial cites a lack of comorbidity proof or an incomplete weight-loss history. Supply the missing labs or notes.

3.

4. Meet the deadline: Internal appeals typically allow 180 days from the denial date, but act within 30 days to keep momentum.

5. Escalate to external review: If the internal appeal fails, file a request with your state’s designated review organization. Decisions are binding on your insurer.

Manufacturer Copay Cards, LillyDirect, and Other Cost Help

Even with coverage, specialty-tier coinsurance can run hundreds of dollars per month. Lilly offers two main avenues of relief:

Zepbound Savings Card (Commercial insurance): If your plan covers Zepbound, the savings card reduces your out-of-pocket to as little as $25 per 28-day fill, up to a maximum annual benefit of $6,000 (zepbound.com).

LillyDirect (No coverage): For people whose insurance excludes obesity drugs, LillyDirect sells Zepbound directly for $550 per 28-day pen, ships overnight, and includes pharmacist counseling (direct.lilly.com).

Patient assistance: Lilly Cares Foundation may provide free medication for eligible low-income patients without insurance. Applications require proof of income and denial letters.

If Insurance Still Says No: Cash-Pay Alternatives

When multiple appeals fail or your plan permanently excludes weight-loss drugs, paying cash is the only route to treatment. One option is compounded tirzepatide, prepared by 503A pharmacies for individual patients. Through the Rx.com weight loss program, compounded tirzepatide costs from $149 a month on a 12-month plan, with the provider visit and shipping included. Compounded tirzepatide is not FDA-approved and is not the same as any brand-name medication.

Always compare prices: your local pharmacy’s cash price for brand Zepbound can exceed $1,100 per pen, while LillyDirect is roughly half that. Use the Rx.com discount card to see real-time price differences.